Business Wire

Forge Biologics Forms Independent Scientific and Manufacturing Advisory Board with Panel of Gene Therapy Leaders

Share

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today the formation of an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development. The board will serve the traditional functions of a scientific advisory board, with a distinct and strategic emphasis on manufacturing advancements.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005561/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Credit: Forge Biologics

“We are thrilled and privileged to have gathered such a renowned group of experts in gene therapy development and manufacturing to work with us to us deliver quality products to our clients, especially as we accelerate AAV production with our new 5,000L bioreactor,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “The board’s guidance will help focus our mission of manufacturing potentially life-saving therapies to patients suffering from genetic diseases.”

Members of Forge’s inaugural Scientific and Manufacturing Advisory Board include:

  • Steven J. Gray, Ph.D., Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center. Dr. Gray serves as the director of the UTSW Viral Vector Facility. His core expertise is in adeno-associated viral (AAV) gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system. His research focus has also been heavily focused in developing AAV-based treatments for neurological diseases, several of which have translated into clinical trials.
  • Robert Kotin, Ph.D., Executive and scientific co-founder at Stealth Newco; Scientific co-founder of Generation Bio and Frontera Therapeutics; Vice President of Production, Voyager Therapeutics. Dr. Kotin is a preeminent expert in AAV gene therapy manufacturing and the co-inventor of the baculovirus-based AAV production system. He joined Voyager from the National Heart, Lung and Blood Institute of the National Institutes of Health, where he served for more than 20 years in roles of increasing responsibility, most recently as Senior Investigator and Laboratory Chief. Previously, Dr. Kotin served as head of the AAV gene therapy program at Genetic Therapy and as Senior Research Scientist of the Medical Research Division at Lederle Laboratories.
  • Karen Kozarsky, Ph.D., Co-Founder and Chief Scientific Officer, SwanBio Therapeutics. Dr. Kozarsky has over 25 years of experience in gene therapy, with a primary focus on the development of gene therapy for inherited rare diseases utilizing AAV vectors. She has been involved in the development of multiple gene therapy products that are in clinical trials. Previously, Dr. Kozarsky was President of Vector BioPartners, Vice President of R&D at REGENXBIO Inc., and Head of Gene Therapy in the GlaxoSmithKline Biopharmaceutical Center of Excellence for Drug Discovery.
  • Haiyan Ma, Ph.D., Director of Science, Northern Biomolecular Services. Dr. Ma is a scientific leader with over 30 years of experience in academic laboratories, pharmaceutical industry, and contracted research. She has a broad background in molecular and cell biology, applications of cell and gene therapy, bioanalysis of DNA/RNA/proteins, and virology. She led the establishment of a GLP compliant molecular biology lab, and served as Study Director or Contributing Scientist in 150+ studies.
  • Simon N. Waddington, Ph.D., Professor of Gene Therapy at University College London. Dr. Waddington’s research has spanned viral and non-viral gene therapy. He has published in Cell, Nature Medicine, and Science Translational Medicine on Adenovirus, AAV and lentivirus biology. Some of the fruits of this work are in late-stage clinical trials.

The board will advise Forge leadership on strategic direction and goals, specifically in the areas of manufacturing and scientific or therapeutic program development.

“The landscape for clinical gene therapy is constantly evolving, and we are eager to work with our board members to ensure that we are observant, thoughtful and agile in our responses to the developments in the field,” said Erandi De Silva, Ph.D., Co-Founder and Senior Vice President of Product Development at Forge. “We are striving to effectively build strategies to overcome the barriers to efficient manufacturing and development in gene therapy, and this group’s guidance will be invaluable.”

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verdane Partners with Climate Tech Leader Cleanwatts28.6.2022 17:00:00 CEST | Press release

Verdane, the European specialist growth equity investor, through its impact fund Idun, has invested in Cleanwatts, an energy software company on a mission to accelerate global energy decarbonization and alleviate energy poverty. Cleanwatts, which grew year-on-year revenues by 65% in 2021 and expects 2022 revenue growth of more than 200%, offers innovative energy management solutions that help local communities unlock the benefits of optimized renewable energy consumption, generation, storage, trading, and balancing. The partnership, in which Verdane is set to invest up to EUR25m, will draw on Verdane’s deep expertise of scaling SaaS companies, international network and in-house team of operating specialists. Cleanwatts is a Portuguese energy management software company that deploys renewable energy communities (RECs) in countries with advanced legal frameworks and policies that enable the activation of local energy markets. The company operates in Portugal (HQ), Italy, Spain, and the U

Andersen Global Enters New Zealand With the Addition of Two Collaborating Firms28.6.2022 15:30:00 CEST | Press release

Andersen Global establishes tax and legal capabilities in New Zealand through Collaboration Agreements with two Auckland-based firms – law firm Turner Hopkins, and tax and advisory firm Bellingham Wallace. The firms maintain deep connections in the region and will play a pivotal role in driving business and delivering integrated, global solutions to create long-term value for clients. Turner Hopkins was founded in 1923, and for nearly 100 years, has provided full-service capabilities in real estate, corporate and commercial law, litigation, finance, employment law, family, private client, estate and immigration. Turner Hopkins’ interdisciplinary team of professionals has vast experience working across a suite of industries and addressing client needs with comprehensive, customized solutions. “We pride ourselves on our client-focused approach and our commitment to ensuring that we retain the highest caliber of lawyers and professionals, which has allowed us to maintain a competitive edg

Synaptics Selects Allegro DVT’s VVC Compliance Streams28.6.2022 15:30:00 CEST | Press release

Allegro DVT, the leading provider of video codec compliance test suites and semiconductor video IPs, today announced that Synaptics Incorporated, one of the world's largest fabless semiconductor companies, has selected Allegro DVT’s VVC test streams to ensure full compliance of Synaptics’ products with the new emerging VVC video compression standard. Versatile Video Coding (VVC), also known as H.266, is the latest video compression standard that was finalized in 2020. It is the successor of HEVC/H.265 and was conceived to achieve two primary goals: improved compression performance and versatility to support a wide range of video applications such as mobile telephony, VOD, Broadcasting, OTT streaming, videoconferencing, screen content, 360° and scalable coding. Craig Stein, SVP and GM of Mobile and IoT at Synaptics, commented, “The depth and breadth of testing that Allegro’s VVC test suite solution provides ensures Synaptics’ VVC decoder implementation is robust and fully compliant with

TA Announces Advantive, a New Mission-Critical Software Provider for Specialty Manufacturing and Distribution Businesses28.6.2022 15:13:00 CEST | Press release

TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005803/en/ Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida. Benoit de la Tour,

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer28.6.2022 15:00:00 CEST | Press release

SonALAsense, a pioneer in the development of SONALA-001 and sonodynamic therapy (SDT), a new drug-device combination developed to manage deadly cancers so patients can become survivors, today announced clinical, organizational and growth updates. It is the only company with SDT in clinical trials. “At SonALAsense, we have been on a journey to develop a non-invasive treatment option for patients with rare brain cancers who often have little hope,” said Mark de Souza, PhD, Founder and Chief Executive Officer. “Today we are excited to announce the culmination of our hard work as we confidently advance SDT into clinical trials as the only non-invasive drug-device combination therapy for the treatment of recurrent glioblastoma multiforme (rGBM) and diffuse intrinsic pontine glioma (DIPG).” Clinical Update SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM. The DIPG trial is actively recruiting and the rGBM clinical trial will begin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom